A1C & diabetes research

1. A. J. Rose et al. Does Opioid Therapy Affect Quality of Care for Diabetes Mellitus? Am J Manag Care 15(4):217–224 (2009).
2. J. Liu et al. Tumor suppressor p53 and metabolism. J Mol Cell Biol 11(4):284–292 (2019).
3. Che-Pei Kung and M. E. Murphy. The role of the p53 tumor suppressor in metabolism and diabetes. J Endocrinol 231(2):R61–R75 (2016).
4. Chantal Mathieu et al. Efficacy and Safety of Dapagliflozin in Patients With Inadequately Controlled Type 1 Diabetes (the DEPICT-2 Study). Diabetes Care 41(9):1938–1946 (2018).
5. C. J. Currie et al. Survival as a Function of HbA1c in People With Type 2 Diabetes: A Retrospective Cohort Study. Lancet 375:481–489 (2010).
6. S. Arnold et al. Further improvement in postprandial glucose control with addition of exenatide or sitagliptin to combination therapy with insulin glargine and metformin. Diabetes Care 33(7):1509–1515 (2010).
7. W. Duckworth et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 360:129–139 (2009).
8. A. S. Adams et al. Medication adherence and racial differences in A1C control. Diabetes Care 31(5):916–921 (2008).
9. Y. J. Cheng et al. Association of A1C and Fasting Plasma Glucose Levels With Diabetic Retinopathy Prevalence in the U.S. Population. Diabetes Care 32:2027–2032 (2009).
10. J. J. Holst et al. GLP-1 receptor agonists: targeting both hyperglycaemia and disease processes in diabetes. Diabetes Res Clin Pract 85:1–3 (2009).
11. M. E. Halkos et al. Elevated preoperative hemoglobin A1c level is predictive of adverse events after coronary artery bypass surgery. Thorac Cardiovasc Surg 136:631–640 (2008).
12. S. Joo et al. Habitual snoring is associated with elevated hemoglobin A1c levels in non-obese middle-aged adults. J Sleep Res 15(4):437–444 (2006).
13. G. A. Herman et al. Pharmacokinetics and pharmacodynamic effects of the oral DPP-4 inhibitor sitagliptin in middle-aged obese subjects. J Clin Pharmacol 46:876–886 (2006).
14. J. J. Fenton et al. Quality of preventive care for diabetes: effects of visit frequency and competing demands. Ann Fam Med 4:32–39 (2006).
15. E. Bonora et al. Prevalence and correlates of post-prandial hyperglycaemia in a large sample of patients with type 2 diabetes mellitus. Diabetologia 49:846–854 (2006).
16. M. Lankisch et al. Basal insulin and oral antihyperglycemic therapy (BOT) plus a single dose of insulin glulisine. Diabetes 55 Suppl 1, Abstract 514-P (2006).
17. D. M. Nathan et al. Management of hyperglycemia in type 2 diabetes: a consensus algorithm. Diabetes Care 29:1963–1972 (2006).
18. R. J. Heine et al. Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes. Ann Intern Med 143:559–569 (2005).
19. R. Gianani and G. S. Eisenbarth. The stages of type 1A diabetes. Immunol Rev 204(1):232–249 (2005).
20. R. H. A. Becker et al. Insulin glulisine, a new rapid-acting insulin analogue. Exp Clin Endocrinol Diabetes 113:435–443 (2005).
21. J. Rosenstock et al. Inhaled insulin improves glycemic control when substituted for or added to oral combination therapy in type 2 diabetes. Ann Intern Med 143:549–558 (2005).
22. D. Edelman et al. Utility of hemoglobin A1c in predicting diabetes risk. J Gen Intern Med 19:1175–1180 (2004).
23. M. T. Sheehan. Current therapeutic options in type 2 diabetes mellitus. Clin Med Res 1:189–200 (2003).
24. R. Derr et al. Is HbA1c Affected by Glycemic Instability? Diabetes Care 26:2728–2733 (2003).
25. C. L. Rohlfing et al. Defining the relationship between plasma glucose and HbA1c. Diabetes Care 25:275–278 (2002).
26. M. Chandalia et al. Beneficial Effects of High Dietary Fiber Intake in Patients with Type 2 Diabetes Mellitus. N Engl J Med 342:1392–1398 (2000).
27. J. Sidarov et al. Disease Management for Diabetes Mellitus: Impact on Hemoglobin A1C. Am J Manag Care 6(11):1217–1226 (2000).
28. J. A. Karjalainen et al. A Bovine albumin peptide as a possible trigger of Insulin-dependent diabetes mellitus. N Engl J Med 327:302–307 (1992).
29. A. G. Bertoni. Achieving control of diabetic risk factors in primary care settings. Am J Manag Care 7(4):411–421 (2001).
30. J. S. Schwartz et al. Glycosylated hemoglobin assays in the management and diagnosis of diabetes mellitus. Ann Intern Med 101:710–713 (1984).
31. H. Rochman. Hemoglobin A1c and Diabetes Mellitus. Ann Clin Lab Sci 10(2):111–115 (1980).
32. R. Dolhofer and O. Wieland. Increased glycosylation of serum albumin in diabetes mellitus. Diabetes 24:417–422 (1980).
33. H. Bunn et al. The glycosylation of hemoglobin: relevance to diabetes mellitus. Science 200(4337):21–27 (1978).
34. X. Zhang et al. A1C Level and Future Risk of Diabetes: A Systematic Review. Diabetes Care 33(7):1665–1673 (2010).

Reviewed by Ben Bird. Last updated: April 2026